Treatment with defactinib showed an increase in FAK, paxillin, and dual FAK-paxillin containing focal adhesions from 0.1 to 3.1 M, but at higher doses, defactinib was able to reduce the amount of FAK and paxillin containing FAs with an IC 50 value of 11.11 M and 18.65 M respectively (Fig
This was correlated with a loss of synaptic plasticity the process by which neurons grow, change or develop stronger connections through activity which is a crucial part of memory and learning
It is not intended to diagnose, treat, cure, or prevent disease in humans, and it is not FDA-approved as a drug or therapeutic agent
it was calculated using the following equation: where, Q s is the cumulative drug permeation per unit area (gcm 2 ), C sn is the drug concentration measured in the receptor fluid at n sampling intervals (gmL 1 ), V S is the volume of the receptor pool (13 mL), is the cumulative drug concentration in the receptor fluid, S is the sampling volume (2 mL), and A S is the effective diffusion area (1.0 cm 2 )
chronic indigestion, loss of appetite, nervous manifestations
Some people experience temporary itching or swelling where the needle entered
